Login
$VCYT
$24.09 -$0.24 (0.99%) Live

$VCYT 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth

14 Sep 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

Exhibit 2.1 EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THE OMITTED INFORMATION HAS BEEN MARKE...

30 Jul 2026 8-K: Results of Operations and Financial Condition

Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively

11 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

(ADOPTED BY THE BOARD OF DIRECTORS ON APRIL 12, 2023, AS AMENDED JUNE 12, 2024, JUNE 17, 2025 AND JUNE 10, 2026)

05 May 2026 8-K: Results of Operations and Financial Condition

Grew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively

16 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

On March 16, 2026, Veracyte, Inc. (the “Company”) announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026.

25 Feb 2026 8-K: Results of Operations and Financial Condition

Grew fourth quarter total revenue to $140.6 million, an increase of 19%

12 Jan 2026 8-K: Results of Operations and Financial Condition

Grew full-year revenue to between $515 million and $517 million, an increase of 16%

04 Nov 2025 8-K: Results of Operations and Financial Condition

Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively

06 Aug 2025 8-K: Results of Operations and Financial Condition

Grew total revenue to $130.2 million and testing revenue to $122.3 million, representing increases of 14% year-over-year

18 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Aff...

07 May 2025 8-K: Results of Operations and Financial Condition

Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18%

24 Feb 2025 8-K: Results of Operations and Financial Condition

Grew fourth quarter total revenue to $118.6 million, an increase of 21%

06 Nov 2024 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., November 6, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024.

04 Sep 2024 8-K: Departure/Election of Directors or Officers; Compensation

On September 3, 2024, following the recommendation from the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Veracyte, Inc. (the “Company”), the Board appointed Tom Miller, Ph.D., and Brent Shafer ...

06 Aug 2024 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., August 6, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2024.

13 Jun 2024 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Aff...

07 May 2024 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., May 7, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024.

22 Mar 2024 8-K: Other Events

As counsel to Veracyte, Inc. a Delaware corporation(the “Company”), we deliver this opinion with respect to certain matters in connection with the offering of up to (a) 1,016,965 shares (the “Shares”) of the Company’s common stock, par v...

29 Feb 2024 8-K: Other Events

As counsel to Veracyte, Inc. a Delaware corporation (the “Company”), we deliver this opinion with respect to certain matters in connection with the offering of up to (a) 1,681,384 shares (the “Shares”) of the Company’s common stock, par ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support